Literature DB >> 10227435

The mechanisms of acceleration of repopulation in squamous epithelia during daily irradiation.

K R Trott1.   

Abstract

Recent experimental data relating to the mechanisms of accelerated repopulation during daily fractionated irradiation are reviewed. There is evidence indicating that acceleration of repopulation is an active response towards the progressively accumulating radiation damage which is characteristic for squamous cell carcinomas and their tissue of origin, i.e. normal squamous epithelium. Whereas little is known about the mechanisms in tumours, various aspects of the trigger and the biological mechanisms have recently been elucidated in normal squamous epithelium. It is reasonable to expect that some of them might also operate in squamous cell carcinomas. Acceleration is due to the loss of asymmetry of stem cell divisions. This may be associated with changes in the keratinocyte differentiation pattern leading to a functionally defective, parakeratotic and hyperproliferative epithelium. This occurs at a certain level of tissue injury. Although related to the time of incipient erythema, the trigger is not the inflammatory response itself or the functional insufficiency of the irradiated epithelium. Rather, the trigger is directly related to the progressive hypoplasia which causes changes in intercellular communication. There is also evidence that acceleration is modulated by signalling processes between the effector keratinocytes and various mesenchymal cells in the irradiated tissue.

Entities:  

Mesh:

Year:  1999        PMID: 10227435     DOI: 10.1080/028418699431555

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  8 in total

1.  Monte Carlo radiotherapy simulations of accelerated repopulation and reoxygenation for hypoxic head and neck cancer.

Authors:  W M Harriss-Phillips; E Bezak; E K Yeoh
Journal:  Br J Radiol       Date:  2011-10       Impact factor: 3.039

2.  Influence of stem-cell cycle time on accelerated re-population during radiotherapy in head and neck cancer.

Authors:  L G Marcu; E Bezak
Journal:  Cell Prolif       Date:  2012-07-07       Impact factor: 6.831

3.  Estimate of the accelerated proliferation by protein tyrosine phosphatase (PTEN) over expression in postoperative radiotherapy of head and neck squamous cell carcinoma.

Authors:  P Pedicini; A Fiorentino; G Improta; A Nappi; M Salvatore; G Storto
Journal:  Clin Transl Oncol       Date:  2013-03-05       Impact factor: 3.405

4.  The HYP-RT hypoxic tumour radiotherapy algorithm and accelerated repopulation dose per fraction study.

Authors:  W M Harriss-Phillips; E Bezak; E Yeoh
Journal:  Comput Math Methods Med       Date:  2012-06-19       Impact factor: 2.238

5.  A comparative analysis between sequential boost and integrated boost intensity-modulated radiation therapy with concurrent chemotherapy for locally-advanced head and neck cancer.

Authors:  Gregory Vlacich; Mark J Stavas; Praveen Pendyala; Shaeu-Chiann Chen; Yu Shyr; Anthony J Cmelak
Journal:  Radiat Oncol       Date:  2017-01-13       Impact factor: 3.481

Review 6.  Neoadjuvant chemotherapy prior to preoperative chemoradiation or radiation in rectal cancer: should we be more cautious?

Authors:  R Glynne-Jones; J Grainger; M Harrison; P Ostler; A Makris
Journal:  Br J Cancer       Date:  2006-02-13       Impact factor: 7.640

7.  Short treatment time and excellent treatment outcome in accelerated hyperfractionated radiotherapy for T1 glottic cancer.

Authors:  Yukihisa Tamaki; Yoko Hieda; Rika Yoshida; Takeshi Yoshizako; Takafumi Fuchiwaki; Noriaki Aoi; Kazumasa Sekihara; Kazuhiro Kitajima; Hideyuki Kawauchi; Hajime Kitagaki; Ryohei Sasaki; Taisuke Inomata
Journal:  Nagoya J Med Sci       Date:  2015-11       Impact factor: 1.131

Review 8.  Six fractions weekly as accelerated fraction radiotherapy: Is it applicable for nasopharyngeal cancer? A review.

Authors:  Arundito Widikusumo; Schandra Purnamawati
Journal:  Contemp Oncol (Pozn)       Date:  2019-10-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.